$GILD: Gilead Sciences to report Q1 results after the close https://t.co/xMUJ1S6RNF
@bradloncar I understand the point, and $GILD 's bottom line has surely suffered, but...
otoh, what a beautiful ch… https://t.co/ODN8ARpq87
$GILD O’Day on M&A/biz dev:
We’re best positioned to focus on our areas of expertise, but we may look elsewhere.… https://t.co/xYyK6eJSyA
RT @bradloncar: $GILD Yescarta sales. https://t.co/hP1ZAOKVXm
Gilead posts higher Q1 profit, revenue on increased HIV product sales - FirstWord Pharma https://t.co/Z3G9Ej9Ycp $GILD #pharma
$GILD Q1 "generated $1.4B in oper cash flow, repaid $750M of debt, paid cash dividends of $817M and utilized $834 M on stock repurchases"
$GILD:
Is Gilead’s Stock and Revenue Free-Fall Finally Bottoming Out?:
https://t.co/wXdGeQZ5fZ
RT @BertrandBio: btw filgo ph3 in AKS slips from 2019 to H1 2020 $GLPG $GILD
$GILD Q1 HIV sales +13%, HCV -21%, Yescarta +140%, other -6.5% YoY
RT @biotechradar_eu: @hanssherpa indeed $GLPG $GILD https://t.co/hZ480dn3xU
Liking O'Day at $GILD. Not a big fan of the HIV and Hep C franchises...but O'Day brings a strong oncology background.
$GILD $KITE expecting to initiate KITE-037 allo CD19 CAR-T phase 1 next year ---> $CLLS $ALCLS
RT @BertrandBio: btw filgo ph3 in AKS slips from 2019 to H1 2020 $GLPG $GILD
RT @bradloncar: $GILD Yescarta sales. https://t.co/hP1ZAOKVXm
#Options #maxpain chart for $GILD. Free options app https://t.co/wPNDm22czd https://t.co/vlDq9yVPVT
Beat the market with #TeamISW, you need to check it out! $X $ATVI $DFFN $GILD https://t.co/OUf3LOPTpe https://t.co/5WKWmAf4va
[WATCH] Biotechs About To Burst - Here's How To Catch The Move $IBB $XBI $AMGN $AGN $GILD $VRTX $BIIB - click link… https://t.co/jbmt8AT98o
$GILD - Statement of Changes in Beneficial Ownership (4) https://t.co/ZbYJ2Ihnwv
$GILD New Form 4 for Gilead Sciences
From our Stock News Alerts App
$GILD - Statement of Changes in Beneficial Ownership (4) https://t.co/dvMDtvMufI
@bradloncar There isn’t much oncology left outside of Kite within $GILD. If M&A to occur in oncology, it implies mo… https://t.co/27XmqFBKjt
#Gilead #HepC #Sales #snapshot $GILD https://t.co/5pF26ruqes
RT @adamfeuerstein: $GILD O’Day on M&A/biz dev:
We’re best positioned to focus on our areas of expertise, but we may look elsewhere.
We…
$GILD,#anticipated #pipeline #2019 #GILEAD https://t.co/1mJdIcOUeb
$GILD Earnings factoid " this quarter was the first time in three years that Gilead earnings and sales have posted… https://t.co/XqrfM3So8k
RT @biotechradar_eu: $GILD ---> $GLPG filgo slides
nothing on filing timelines (in the slides)
CC coming https://t.co/F26G0cWiDk
RT @_B_I_O_T_E_C_H_: $GILD >1,500 patients treated with #Yescarta to date, commercial market and clinical trials combined
Yescarta authoriz…
RT: $GILD Yescarta https://t.co/lSU4JCCPnv: $GILD Yescarta sales. https://t.co/59JJpRROJ3 https://t.co/Fm7TMEdau2 Via: @bradloncar
@bradloncar I’d wanna own $gild, but past 1 year, I delay the decision 1-2 months, and check back, I see I didn’t miss anything.
RT @semodough: MIZHOU $GILD, Buy, PT: $88.00, Price: $64.87
1Q19 Quick Take ==> Overall Good Quarter. Biktarvy Strength Was Notable. 80% o…
RT @WallStreetBean: $GILD Q1 "generated $1.4B in oper cash flow, repaid $750M of debt, paid cash dividends of $817M and utilized $834 M on…
RT @WallStreetBean: $GILD Q1 rev growth YoY by region: US +8.6%, Euro -12%, other +11%
RT @bradloncar: $GILD Yescarta sales. https://t.co/hP1ZAOKVXm
RT @BertrandBio: btw filgo ph3 in AKS slips from 2019 to H1 2020 $GLPG $GILD
Is $GILD's former golden goose stabilizing? Here's what earnings say #biotech #stocks #investing https://t.co/RSIOOr3XxY
RT @biotechradar_eu: @hanssherpa indeed $GLPG $GILD https://t.co/hZ480dn3xU
$VKTX $GILD $NVO
NASH collaborations are a good start, but: https://t.co/waoM5JYpS3
RT @Trade_The_News: $GILD Reports Q1 $1.76 v $1.62e, Rev $5.28B v $5.31Be (Gilead Sciences Inc)
(More at https://t.co/JZ8bY9U9YT)
This is a Rorschach test. Do you focus on the trendline of the RH side, or the area under the curve? $GILD https://t.co/uDn7JTxicj
RT @_B_I_O_T_E_C_H_: Canaccord Putting cells on a shelf: a dissection of #allogeneic cell therapies for oncology
$SGMO Allogeneic, "off-t…
$GILD CEO on M&A https://t.co/nazwUCSV7T
RT @adamfeuerstein: $GILD O’Day on M&A/biz dev:
We’re best positioned to focus on our areas of expertise, but we may look elsewhere.
We…
$SHAK +6.53%
$X +4.93%
$FLR +1.78%
$GDI +1.27
$FCAU +0.93
$GILD +0.84%
$UAA +0.70%
Popular Stocks: Bull (After Hou… https://t.co/bfdwT8m7Ev
RT @HedgeFundTips: Biotech (top 30 weights) Earnings Estimates/Revisions https://t.co/hxrtqQwR3D $CELG
$GILD
$AMGN
$BIIB
$VRTX
$ILMN
$ALXN…
@PearlF @bradloncar Yes, that really can’t be a division the size of $GILD!
UPDATE 1-Gilead to separate Kite cell therapy unit, posts higher profit @CNBC $gild $ibb https://t.co/1zGHV0UK3I
So does $GILD go with an indication without any commercial assets yet, or just follow BP playbook of therapeutic ar… https://t.co/zmaBLmBYd6
RT @adamfeuerstein: $GILD O’Day on M&A/biz dev:
We’re best positioned to focus on our areas of expertise, but we may look elsewhere.
We…
$GILD Kite Pharma, the cancer-focused cell therapy company it acquired in 2017, will become a separate business un… https://t.co/DZnmI7D32U
Insider alert: Insider Whitley Richard James of $GILD bought 9,534 shares @ $209,891.01
$GILD:
New Insider Filing on
Director
RICHARD JAMES WHITLEY:
https://t.co/osJ8I9tc0c
$XBI $GILD: Whitley Richard James (Director) disposed stocks worth $619,934 and exercised options worth $209,891 https://t.co/YVEay4cV1a
$SPY $GILD: Whitley Richard James (Director) disposed stocks worth $619,934 and exercised options worth $209,891 https://t.co/YVEay4cV1a
$GILD Gilead Sciences, Inc. SEC Filing: Form 4 https://t.co/s9E7VLor4C
HIV franchise is the backbone of $GILD and the only reason the company is even investable https://t.co/1BfVdECotn
$GILD 配当利回り3.86%
どうなんやろ?
@DewDiligence @jq1234t @bradloncar I think they just overpaid and prob segregating $KITE as a condition prior to se… https://t.co/rKll0pzYLu
Explore #fundamental numbers and pros and cons for $GILD https://t.co/IFnkAQiwhE
RT @theflynews: Fly Intel: After Hours Movers $UIS $FTNT $CC $WW $OLED $ZIXI $CARB $MELI $CBLK $MNST $SHAK $MTZ $FNKO $CRC $UCTT $X $ALDR $…
Gilead Sciences, Inc. $GILD Announces $0.63 Quarterly Dividend https://t.co/oAJPO773WW #stocks
$TEVA settled -2.2% at $14.90 on earnings. The daily candle is a hollow red reversal, and offers at least a s/t flo… https://t.co/9QstOfVYDw
Gilead Sciences, Inc. $GILD Plans $0.63 Quarterly Dividend https://t.co/iZwnElFLxX
RT @DewDiligence: @bradloncar @jq1234t This feels like a case of: Buyer's regret re (overpaymnt4) $KITE acquisition—>new $GILD mgmt—>renewe…
@bradloncar @jq1234t This feels like a case of: Buyer's regret re (overpaymnt4) $KITE acquisition—>new $GILD mgmt—>… https://t.co/4M8iy8KkdZ
RT @DewDiligence: @jq1234t @bradloncar I don't buy Brad's notion that $KITE has been separated b/c cell therapy requires special "entrepren…
@jq1234t @bradloncar I don't buy Brad's notion that $KITE has been separated b/c cell therapy requires special "ent… https://t.co/KNVWeZlV1a
RT @theflynews: Fly Intel: After Hours Movers $UIS $FTNT $CC $WW $OLED $ZIXI $CARB $MELI $CBLK $MNST $SHAK $MTZ $FNKO $CRC $UCTT $X $ALDR $…
RT @theflynews: Fly Intel: After Hours Movers $UIS $FTNT $CC $WW $OLED $ZIXI $CARB $MELI $CBLK $MNST $SHAK $MTZ $FNKO $CRC $UCTT $X $ALDR $…
Fly Intel: After Hours Movers $UIS $FTNT $CC $WW $OLED $ZIXI $CARB $MELI $CBLK $MNST $SHAK $MTZ $FNKO $CRC $UCTT $X… https://t.co/c7eg1UCyhX
HIV and hep c had its role in bringing the company to where it is but it’s time to move on, good move by $GILD as I… https://t.co/mii3Ma3Z6Z
Pre-Mkt, After Mkt, and Bear Scans help you find stock setups faster. $X $ATVI $FNKO $GILD https://t.co/yAOmGKQEmJ https://t.co/dlBVwFvxFE
Don't miss our next FREE OPTION TRADE. Sign up for our Daily Free Trades at https://t.co/waWLpblUXp $NVDA $TSLA $GS $GILD $F $GOOGL $FB
$GOOGL $TWTR $SNAP $CLF $TTWO $ALXN $DIS $BP $CLX $SYY $GM $GILD $CMG $GRUB $EA $STX $SPOT $AMG $SAIA $RL $CNC $EL… https://t.co/XqL52IwF9b
RT @semodough: Baird $GILD GILD remains a wait and see story, despite its optical cheapness, as the pipeline needs an overhaul (selonsertib…
Baird $GILD GILD remains a wait and see story, despite its optical cheapness, as the pipeline needs an overhaul (se… https://t.co/LMR1Kzwsvc
RT @BioCentury: New CEO O’Day touts cell therapies as Gilead beats on EPS $GILD https://t.co/UYb1SNMdCX
$ROG $GILD New Gilead CEO O'Day Says Boosting Drug Pipeline Is Top Priority via https://t.co/dU2ohMsCEH
New CEO O’Day touts cell therapies as Gilead beats on EPS $GILD https://t.co/UYb1SNMdCX
$GOOGL $TWTR $SNAP $CLF $TTWO $ALXN $DIS $BP $CLX $SYY $GM $GILD $CMG $GRUB $EA $STX $SPOT $AMG $SAIA $RL $CNC $EL… https://t.co/4wWxkMWBtN
RT @PenniesAll: $GOOGL $TWTR $SNAP $CLF $TTWO $ALXN $DIS $BP $CLX $SYY $GM $GILD $CMG $GRUB $EA $STX $SPOT $AMG $SAIA $RL $CNC $EL $UFI $GL…
Do you know that #WallStreet price for $GILD is $81.26 https://t.co/mpDel0oxXd
$GILD Qualitative Analysis of recent earnings identified Gilead Sciences, Inc (NASDAQ: GILD ) business focus on (fd… https://t.co/O8TsWFfC6L
$GILD:
Gilead Sciences, Inc. (GILD) CEO Daniel O’Day on Q1 2019 Results …:
https://t.co/1iEnJmBawv
Gilead Sciences, Inc. $GILD Director Sells $186,104.52 in Stock https://t.co/SwBBDL8Hjn #stocks
Gilead Sciences, Inc. $GILD Director John Francis Cogan Sells 2,868 Shares https://t.co/cltqgvVbi2
RT @semodough: Baird $GILD GILD remains a wait and see story, despite its optical cheapness, as the pipeline needs an overhaul (selonsertib…
$GILD - Gilead Sciences, Inc. (GILD) CEO Daniel O'Day on Q1 2019 Results - Earnings Call Transcript https://t.co/3sVPqWui8Z
RT @adamfeuerstein: Dan O’Day’s opening remarks on the $GILD conference call were 100% on script, meaning you’ve heard the same words from…
RT @adamfeuerstein: $GILD O’Day on M&A/biz dev:
We’re best positioned to focus on our areas of expertise, but we may look elsewhere.
We…
@adamfeuerstein Getting where we need to go... $GILD https://t.co/s7R3SadQyz
@GileadSciences You've save many a friends lives... Thank You!! $GILD
Unicorn Bay rating for $GILD is 2.89 out of 5. https://t.co/jD70zGcNYE
I went long on $GDDY $MNST and $GILD due to their earnings reports coming out. All estimates looked good so hoping… https://t.co/itbbcj8p6I
RT @jq1234t: @PearlF @bradloncar Yes, that really can’t be a division the size of $GILD!
Gilead Sciences, Inc. (GILD) CEO Daniel O'Day on Q1 2019 Results - Earnings Call Transcript $GILD $GLPG
https://t.co/KZagN3WNJs
$GILD:
Gilead Sciences Inc (GILD) Q1 2019 Earnings Call Transcript:
https://t.co/TpNh4JtKkL
We calculated 63-day Expected Return of $GILD for you: -5.83% https://t.co/mTgAzTSiLD
RT @biotechradar_eu: $GILD ---> $GLPG filgo slides
nothing on filing timelines (in the slides)
CC coming https://t.co/F26G0cWiDk
Gilead to separate Kite cell therapy unit, posts higher profit $GILD https://t.co/ONlcK5A2py via @Reuters @Nasdaq
$GILD - Correction to Gilead Sciences Article https://t.co/zDnCQjeSCn
RT @eWhispers: #earnings after the close
$ATVI $X $ANET $GILD $FTNT $SWKS $PLNT $OLED $FSLR $EXPE $DATA $SHAK $FNKO $MELI $NVAX $GDDY $MN…
Gilead Sciences $GILD Upgraded to “Hold” at BidaskClub https://t.co/xvk0oNr76k
Gilead Sciences $GILD Earns Buy Rating from Cowen https://t.co/qt1rPTYhQd
Wondering about risks of $GILD? The 63-day volatility is 10.32% https://t.co/YrfwPBdUuU
Recommendation #HOLD for $GILD with UB rating - 2.89 out of 5. https://t.co/Kn4eAPYUj7
Gilead Sciences $GILD Announces Quarterly Earnings Results, Beats Expectations By $0.23 EPS https://t.co/VcD91dvpjB #stocks
RT @eWhispers: #earnings after the close
$ATVI $X $ANET $GILD $FTNT $SWKS $PLNT $OLED $FSLR $EXPE $DATA $SHAK $FNKO $MELI $NVAX $GDDY $MN…
2019-05-02 Short sale volume (not short interest) for $AMGN is 41%. https://t.co/udZXOA7QoF $BIIB 46% $CELG 36% $GILD 37% $ALXN 56%
RT @_B_I_O_T_E_C_H_: Jefferies YEE: $GILD $KITE Yescarta also solid at $96M and generally in-line as it continues to grow each quarter and…
Jefferies YEE: $GILD $KITE Yescarta also solid at $96M and generally in-line as it continues to grow each quarter a… https://t.co/vAbHbuS7Nu
"We paid cash dividends of $817 million and we repurchased 12 million shares of stock for $834 million." $GILD
"During the first quarter, we generated $1.4 billion in cash from operations and ended the quarter with $30.1 billi… https://t.co/S4a0c4ZEyz
Resultados 'aceptables' de Gilead Sciences: Q1 Non-GAAP EPS of $1.76 beats by $0.16; GAAP EPS of $1.54.
Revenue of… https://t.co/MQuCw8eYRu
$GILD O'Day says they really want to win in cell therapy and continue to invest here (as opposed to bears saying he… https://t.co/cfVDEEHyoB
RT @suhaildarraj: شركة $GILD هي ثاني اكبر شركة في مجال البيوتك (التكنولوجيا الحيوية الطبية ) .. هذه الشركة ظلمت كثيرا بسبب تراجع نتائجها ا…
شركة $GILD هي ثاني اكبر شركة في مجال البيوتك (التكنولوجيا الحيوية الطبية ) .. هذه الشركة ظلمت كثيرا بسبب تراجع نتا… https://t.co/UTpAliETTP
$GOOGL $TWTR $SNAP $CLF $TTWO $ALXN $DIS $BP $CLX $SYY $GM $GILD $CMG $GRUB $EA $STX $SPOT $AMG $SAIA $RL $CNC $EL… https://t.co/0Jv1SQekat
$GOOGL $TWTR $SNAP $CLF $TTWO $ALXN $DIS $BP $CLX $SYY $GM $GILD $CMG $GRUB $EA $STX $SPOT $AMG $SAIA $RL $CNC $EL… https://t.co/VpR4koydTv
RT @eWhispers: #earnings after the close
$ATVI $X $ANET $GILD $FTNT $SWKS $PLNT $OLED $FSLR $EXPE $DATA $SHAK $FNKO $MELI $NVAX $GDDY $MN…
RT @behindthebid: 163 companies reporting earnings today / last night. Most notable are Gilead $GILD, Activision Blizzard $ATVI, Cognizant…
163 companies reporting earnings today / last night. Most notable are Gilead $GILD, Activision Blizzard $ATVI, Cog… https://t.co/xiQHhNyicO
So far, only few preclinical studies have been done with pd1/pdl1 in HBV model from $BMY and $GILD… https://t.co/kbvkqqUey2
$GILD earnings #HBV side
Gilead continue to focus its effort on the immune pathway (especially adaptive immunity) t… https://t.co/1UpkpUNZfI
$GILD:
Gilead Sciences Returns to Growth in the First Quarter:
https://t.co/fGziB39AEp
RT @suhaildarraj: شركة $GILD هي ثاني اكبر شركة في مجال البيوتك (التكنولوجيا الحيوية الطبية ) .. هذه الشركة ظلمت كثيرا بسبب تراجع نتائجها ا…
RT @behindthebid: 163 companies reporting earnings today / last night. Most notable are Gilead $GILD, Activision Blizzard $ATVI, Cognizant…
ACTIVE TRADERS Try one of these FREE trading guides:
https://t.co/MveriXtytK
$NFLX $TSLA $AAPL $GILD $GS $FB $AMZN $GOOGL $NVDA
$GILD $NOVN Novo Nordisk Considers Move TowardsGene Therapy via https://t.co/dU2ohMsCEH
RT @JohnCendpts: Dan O’Day’s to-do list for Gilead: Recruit a Kite CEO, press the pedal on next-gen cell therapies and start buying stuff
$…
Cowen Reiterates “Buy” Rating for Gilead Sciences $GILD https://t.co/qrDmEuCRhC #stocks
Dan O’Day’s to-do list for Gilead: Recruit a Kite CEO, press the pedal on next-gen cell therapies and start buying… https://t.co/kPyrZqMO2S
Watching $TSLA $QCOM $GILD
Stocks Making Moves PM: $BA $TSLA $NWL $MAR $DISH $BRK.B $ATVI $CBS $EXPE $GILD $FB $SHAK $GDDY $VZ $WW & More https://t.co/7XIM5gY698
$GILD:
Gilead Sciences Has Right Prescription on First-Quarter Earnings:
https://t.co/MMtU28KXyQ
RT @zbiotech: *GILEAD REITERATES FULL YEAR 2019 GUIDANCE
$GILD
RT @JohnCendpts: Dan O’Day’s to-do list for Gilead: Recruit a Kite CEO, press the pedal on next-gen cell therapies and start buying stuff
$…
$GILD (+0.9% pre) Gilead stock ticks higher as earnings beat Street, revenue doesn't - MW
https://t.co/lNyznPYfVw
$BSRC Momentum in progress.
$CVX $MO $PM $PG $KO $NVDA $AMD $AAPL $BIDU $CSCO $C $T $INTC $XOM $GOOGL $FB $AMZN… https://t.co/IUvgCMSsWd
RT @suhaildarraj: شركة $GILD هي ثاني اكبر شركة في مجال البيوتك (التكنولوجيا الحيوية الطبية ) .. هذه الشركة ظلمت كثيرا بسبب تراجع نتائجها ا…
Detail on new WF upgrade, which was based on **a survey of #NASH prescribing MDs** (and $GILD study failure).… https://t.co/UoTJwyUIUL
My first Top Idea about @Watkin_Jones on @SeekingAlpha has been published today! https://t.co/AGnYsdFKke $CVX $MO… https://t.co/eXaVNdgUYM
$GILD - O'Day: The Man Of The Hour For Gilead https://t.co/TgWbEWgGYB